Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey

Table 5 Serious adverse events (SAEs) in adults (n = 11) and paediatric patients (n = 5) receiving anakinra

Adults			Children
Patient no.	Disease	SAE	Patient no.	Disease	SAE
1	Gout	Pulmonary abscess	1	sJIA	MAS and EBV infection
2	AOSD	Pneumonia	2	sJIA	MAS and hepatitis
3	AOSD	VZV infection	3	sJIA	MAS, severe lipodystrophy and leishmaniasis*
4	AOSD	MAS and infection	4	sJIA	Death, toxidermia**
5	Schnitzler’s syndrome	Cancer, death	5	sJIA	Scarlet fever
6	MKD	Severe bronchitis
7	Vasculitis	Sinusitis
8	Polychondritis	Cutaneous abscess and osteitis
9	Pustular dermatosis	Septicemia
10	FMF	Quincke oedema
11	GPP	Severe cutaneous allergic reaction

AOSD: adult onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, FMF: familial Mediterranean fever, MKD: mevalonate kinase deficiency. Vasculitis: polyarteritis nodosa. GPP: generalized pustular psoriasis.
MAS: macrophage activation syndrome. EBV: Epstein Barr virus.
*Leishmaniasis in child no. 3 was previously published [41].
**Child no. 4 had a severe sJIA with associated chronic myocarditis; severe toxidermia developed with anakinra treatment and he died 3 days after anakinra withdrawal due to disease flare and acute myocarditis.

ISSN: 1750-1172